ProQR Therapeutics NV (PRQR) Earns Buy Rating from JMP Securities
ProQR Therapeutics NV (NASDAQ:PRQR)‘s stock had its “buy” rating reissued by equities researchers at JMP Securities in a note issued to investors on Tuesday.
A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Sabby Management LLC boosted its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned about 0.64% of ProQR Therapeutics NV worth $732,000 at the end of the most recent quarter.
ProQR Therapeutics NV (NASDAQ:PRQR) traded up 1.36% during mid-day trading on Tuesday, hitting $5.98. 3,389 shares of the stock traded hands. The stock’s market capitalization is $139.61 million. ProQR Therapeutics NV has a one year low of $3.48 and a one year high of $20.05. The company has a 50 day moving average price of $5.22 and a 200-day moving average price of $4.98.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/proqr-therapeutics-nv-prqr-earns-buy-rating-from-jmp-securities/
ProQR Therapeutics NV (NASDAQ:PRQR) last announced its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.00. Equities analysts anticipate that ProQR Therapeutics NV will post ($2.14) earnings per share for the current fiscal year.
Several other analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research note on Wednesday, August 31st. Leerink Swann reiterated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Thursday, August 18th. Finally, Chardan Capital assumed coverage on shares of ProQR Therapeutics NV in a research note on Monday, June 20th. They issued a “neutral” rating and a $4.50 price objective for the company. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ProQR Therapeutics NV currently has a consensus rating of “Buy” and a consensus price target of $15.94.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ProQR Therapeutics NV and related companies with MarketBeat.com’s FREE daily email newsletter.